Back to News
Market Impact: 0.18
Standigm and Protai Launch Joint R&D Program to Design Selective Molecular Glue Degraders Using Structural Proteomics and Generative AI
Source: PR Newswire
Artificial IntelligenceHealthcare & BiotechTechnology & Innovation
Protai and Standigm announced a Korea-Israel collaboration, supported by KORIL-RDF, combining AI-powered structural proteomics with generative drug-design technology. The partnership targets improved selectivity in targeted protein degradation, a key technical challenge in developing precision therapeutics; no financial terms, development milestones, or commercial outlook were disclosed.
AllMind Terminal
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request TrialMarket Sentiment
Overall Sentiment
mildly positive
Sentiment Score
0.30
More News
- Companies promised AI gains— here's how the payoff showed up in earnings
- AWS grows 39% and Amazon will spend even more on AI in 2027
- U.S workers just took home their smallest share of capital since at least 1947—and the lowest ever recorded
- Stocks started the week with promise but ended in despair. Our take on the big reversal
- Fears over $828 billion AI capex spending spree help erase $1 trillion in market value
- Intel stock plunges 29%. Analysts urge caution on buying the dip